XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
REVENUES (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Contract Asset
The following table summarizes our contract assets:
(in millions)September 30,
2022		December 31,
2021
Contract manufacturing services$65 $50 
Software sales44 45 
Bundled equipment and consumable medical products contracts120 100 
Contract assets$229 $195 
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions)September 30,
2022		December 31,
2021
Prepaid expenses and other current assets$106 $84 
Other non-current assets123 111 
Contract assets$229 $195 
Accrued expenses and other current liabilities$158 $162 
Other non-current liabilities82 84 
Contract liabilities$240 $246 
The following table summarizes contract liability activity for the nine months ended September 30, 2022. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Nine months ended
September 30, 2022
Balance at beginning of period$246 
New revenue deferrals460 
Revenue recognized upon satisfaction of performance obligations(463)
Currency translation(3)
Balance at end of period$240 
Net Sales from Contracts with Customers by Global Business Unit
The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:
Three Months Ended September 30,
20222021
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Renal Care 1
$240 $702 $942 $222 $759 $981 
Medication Delivery 2
475 250 725 490 257 747 
Pharmaceuticals 3
173 352 525 188 401 589 
Clinical Nutrition 4
92 139 231 88 156 244 
Advanced Surgery 5
141 106 247 135 114 249 
Acute Therapies 6
53 105 158 69 116 185 
BioPharma Solutions 7
99 73 172 109 97 206 
Patient Support Systems 8
301 79 380 — — — 
Front Line Care 9
209 70 279 — — — 
Surgical Solutions 10
38 38 76 — — — 
Other 11
28 10 38 18 7 25 
Total Baxter$1,849 $1,924 $3,773 $1,319 $1,907 $3,226 
Nine Months Ended September 30,
20222021
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Renal Care 1
$690 $2,077 $2,767 $655 $2,212 $2,867 
Medication Delivery 2
1,406 735 2,141 1,345 751 2,096 
Pharmaceuticals 3
494 1,080 1,574 550 1,137 1,687 
Clinical Nutrition 4
266 422 688 255 460 715 
Advanced Surgery 5
428 310 738 405 317 722 
Acute Therapies 6
179 340 519 211 369 580 
BioPharma Solutions 7
226 265 491 218 306 524 
Patient Support Systems 8
880 247 1,127 — — — 
Front Line Care 9
618 237 855 — — — 
Surgical Solutions 10
111 112 223 — — — 
Other 11
72 31 103 58 21 79 
Total Baxter$5,370 $5,856 $11,226 $3,697 $5,573 $9,270 
1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.
2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.
3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.
4Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.
5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.
6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).
7BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies.
8Patient Support Systems includes sales of our connected care solutions: devices, software, communications and integration technologies and smart beds.
9Front Line Care includes sales of our integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology, vision screening and physical assessment.
10Surgical Solutions includes sales of our surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.
11Other includes sales of miscellaneous product and service offerings.
Sales-type Lease, Lease Income
The components of lease revenue for the three and nine months ended September 30, 2022 and 2021 were:
(in millions)Three months ended September 30, 2022Nine months ended September 30, 2022
Sales-type lease revenue$3 $11 
Operating lease revenue145 380 
Variable lease revenue9 41 
Total lease revenue$157 $432 
(in millions)Three months ended September 30, 2021Nine months ended September 30, 2021
Sales-type lease revenue$3 $19 
Operating lease revenue21 90 
Variable lease revenue27 59 
Total lease revenue$51 $168 
Operating Lease, Lease Income
The components of lease revenue for the three and nine months ended September 30, 2022 and 2021 were:
(in millions)Three months ended September 30, 2022Nine months ended September 30, 2022
Sales-type lease revenue$3 $11 
Operating lease revenue145 380 
Variable lease revenue9 41 
Total lease revenue$157 $432 
(in millions)Three months ended September 30, 2021Nine months ended September 30, 2021
Sales-type lease revenue$3 $19 
Operating lease revenue21 90 
Variable lease revenue27 59 
Total lease revenue$51 $168